Targeted drugs are a cornerstone of personalized medicine, yet come with important drawbacks. They restrain disease progression -- but rarely eradicate the cancer. Patients therefore need to take the drugs essentially forever, exposing them to severe side effects and incurring high costs for the healthcare system. Combination therapies could potentially overcome these limitations. A new study shows how epigenetic analysis and automated microscopy help prioritize new drug combinations for leukemia therapy.
from Top Health News -- ScienceDaily http://bit.ly/2HANDcJ
Subscribe to:
Post Comments (Atom)
Omicron has cast a shadow of uncertainty on growth outlook: IndiGo CEO
However, the airline is stronger now when compared to situation in 2020 during the first wave of the pandemic, says Ronojoy Dutta from Com...
-
While sales to original equipment manufacturers declined 16.3% year on year in FY20, the replacement market sales declined by a modest 2.6% ...
-
India's passenger vehicle sales are expected to grow between 3-5 percent in the current fiscal year, after expanding at the slowest pace...
-
The earnings momentum has been quite resilient and the policy momentum quite focused towards improving the infrastructure and attractiveness...
No comments:
Post a Comment